The role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (DOACs)

  • Email
  • Help

Details

TitleThe role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (DOACs)
Date23/11/2015 - 23/11/2015
LocationEuropean Medicines Agency, London, UK
SummaryThis EMA workshop will bring together experts and stakeholders to discuss the utility of pharmacokinetic (PK) and pharmacodynamic (PD) measurements in the clinical use of the new direct oral anticoagulants (DOACs) and whether those could enhance the benefit-risk profile of these medicines by further reducing the risk of major bleedings while maintaining or improving the protection against thromboembolic events. The objectives of the workshop are to improve the understanding of the clinical use of DOACs, issues in relation to PK and PD measurements as well as priorities in future research.

All documents

Name Language First published Last updated
Programme - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (English only) 2015-10-16 2015-11-17
Workshop - the role of pharmacodynamic and pharmacokinetic measurements in the use of direct oral anticoagulants: Background document (English only) 2015-11-20  
Proceedings of the workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (English only) 2016-01-07  
List of participants - Workshop on the role of pharmacokinetic and pharmacodynamic measurements in the use of direct oral anticoagulants (English only) 2016-01-07  
Presentation - DOACs: the patient perspective (Christine Dehn) (English only) 2016-01-07  
Presentation - Challenging patients on DOACs and need for monitoring (Menno Huisman) (English only) 2016-01-07  
Presentation - Management of DOAC in clinical praxis (Peter J Svensson) (English only) 2016-01-07  
Presentation - What can we do now and what are the gaps in our knowledge? The direct thrombin inhibitor (dabigatran etexilate) (Marie Louise S. Christiansen) (English only) 2016-01-07  
Presentation - Session 2: What can we do now and what are the gaps in our knowledge? The direct factor Xa inhibitors (rivaroxaban, apixaban, edoxaban) (Antonio Gómez-Outes) (English only) 2016-01-13  
Presentation - Session 3: the analytical part - Measuring the concentration of the direct thrombin inhibitor (dabigatran etexilate) (François Mullier) (English only) 2016-01-07  
Presentation - Measuring concentrations of Rivaroxaban, Apixaban, Edoxaban: methods and challenges (Steve Kitchen) (English only) 2016-01-07  
Presentation - NOAC future perspectives: academic perspective (Hugo ten Cate) (English only) 2016-01-07  
Presentation - Future perspectives: how to better use the available data, how to fill the gaps in our knowledge about PK/PD, future ways on how knowledge can be obtained (Jörg Kreuzer) (English only) 2016-01-07  
Presentation - Industry perspective: Bayer/Janssen (Scott D. Berkowitz) (English only) 2016-01-07  
Presentation - Industry perspective: Pfizer - Eliquis® (apixaban) (English only) 2016-01-07  
Presentation - Session 4: future perspectives - What could be done? Industry perspective (Daiichi Sankyo) (English only) 2016-01-07  

Media Videos


Video recording

A video recording is now available.

To view use the ‘Multimedia’ tab.

Related information